SWAV Shockwave Medical

Shockwave Medical to Participate in the 39th Annual Canaccord Genuity Global Growth Conference

Shockwave Medical to Participate in the 39th Annual Canaccord Genuity Global Growth Conference

SANTA CLARA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with analysts and investors at the upcoming 39th Annual Canaccord Genuity Global Growth Conference being held from August 7-8, 2019 in Boston, MA.

The Shockwave session is scheduled to take place Wednesday, August 7, 2019 at 8:30 a.m. Eastern Time. Investors and the general public are invited to listen to a live webcast of the presentation at . Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the presentation will be available later that day.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated by establishing a new standard of care with Intravascular Lithotripsy (IVL) technology. The company’s differentiated and proprietary IVL approach to calcium modification uses sonic pressure waves to safely and effectively fracture problematic calcium throughout the cardiovascular system in a wide and growing number of applications. For more information, visit .

Media Contact:

Scott Shadiow

+1.317.432.9210

Investor Contact:

Debbie Kaster, Gilmartin Group

EN
23/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shockwave Medical

 PRESS RELEASE

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...

 PRESS RELEASE

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-W...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch